董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Steven H. Stein | 男 | Director | 50 | 未披露 | 未持股 | 2017-03-31 |
| Robert E. Hoffman | 男 | Director | 51 | 7.89万美元 | 未持股 | 2017-03-31 |
| Faheem Hasnain | 男 | Director | 58 | 7.26万美元 | 未持股 | 2017-03-31 |
| Thomas Malley | 男 | Director | 48 | 7.01万美元 | 未持股 | 2017-03-31 |
| Troy Wilson | 男 | President and Chief Executive Officer, Chairman | 48 | 104.60万美元 | 未持股 | 2017-03-31 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Yi Liu | 男 | Chief Scientific Officer | 49 | 未披露 | 未持股 | 2017-03-31 |
| Heidi Henson | 女 | Chief Financial Officer and Secretary | 51 | 未披露 | 未持股 | 2017-03-31 |
| Antonio Gualberto | 男 | Chief Medical Officer | 52 | 76.23万美元 | 未持股 | 2017-03-31 |
| Annette North | 女 | Senior Vice President, General Counsel | 51 | 71.02万美元 | 未持股 | 2017-03-31 |
| Pingda Ren | 男 | Senior Vice President, Chemistry and Pharmaceutical Sciences | 48 | 未披露 | 未持股 | 2017-03-31 |
| Troy Wilson | 男 | President and Chief Executive Officer, Chairman | 48 | 104.60万美元 | 未持股 | 2017-03-31 |
董事简历
中英对照 | 中文 | 英文- Steven H. Stein
-
StevenH.Stein自2017年1月以来一直担任我们的董事会成员。Stein博士自2015年3月起担任因塞特医疗公司（一家上市生物制药公司）的高级副总裁兼首席医疗官。在此之前，2011年5月至2015年2月，Stein博士担任梦百合公司Novartis Oncology U.S.的美国临床开发与医疗事务高级副总裁，。Stein博士曾在GlaxoSmithKline plc担任Vice President，全球肿瘤学，临床开发以及血液学和支持性护理药物开发主管。Stein博士在南非约翰内斯堡的威特沃特斯兰德大学（University of Witwatersrand）获得医学博士学位。
Steven H. Stein has served as a member of our Board of Directors since January 2017. Dr. Stein has served as Senior Vice President and Chief Medical Officer of Incyte Corporation, a publicly-held biopharmaceutical company, since March 2015. Prior to that, from May 2011 to February 2015 Dr. Stein served as Senior Vice President, U.S. Clinical Development & Medical Affairs at Novartis Oncology U.S., a healthcare company. Dr. Stein worked at GlaxoSmithKline plc as Vice President, Global Oncology, Clinical Development and also as Head of Medicines Development for Hematology and Supportive Care. Dr. Stein earned his M.D. from the University of Witwatersrand in Johannesburg, South Africa. - StevenH.Stein自2017年1月以来一直担任我们的董事会成员。Stein博士自2015年3月起担任因塞特医疗公司（一家上市生物制药公司）的高级副总裁兼首席医疗官。在此之前，2011年5月至2015年2月，Stein博士担任梦百合公司Novartis Oncology U.S.的美国临床开发与医疗事务高级副总裁，。Stein博士曾在GlaxoSmithKline plc担任Vice President，全球肿瘤学，临床开发以及血液学和支持性护理药物开发主管。Stein博士在南非约翰内斯堡的威特沃特斯兰德大学（University of Witwatersrand）获得医学博士学位。
- Steven H. Stein has served as a member of our Board of Directors since January 2017. Dr. Stein has served as Senior Vice President and Chief Medical Officer of Incyte Corporation, a publicly-held biopharmaceutical company, since March 2015. Prior to that, from May 2011 to February 2015 Dr. Stein served as Senior Vice President, U.S. Clinical Development & Medical Affairs at Novartis Oncology U.S., a healthcare company. Dr. Stein worked at GlaxoSmithKline plc as Vice President, Global Oncology, Clinical Development and also as Head of Medicines Development for Hematology and Supportive Care. Dr. Stein earned his M.D. from the University of Witwatersrand in Johannesburg, South Africa.
- Robert E. Hoffman
-
Robert E. Hoffman，自2018年4月起担任Kintara Therapeutics，Inc.董事，自2018年6月起担任Kintara Therapeutics, Inc.董事长，自2021年11月起担任Kintara Therapeutics, Inc.首席执行官兼总裁，自2023年6月起担任Kintara Therapeutics，Inc.临时首席财务官。自2018年10月起，他担任亚狮康药业，Inc.的董事会成员，该公司是一家上市的、专注于临床阶段免疫学的生物制药公司，自2021年4月起担任FibroGenesis，一家临床阶段再生医学公司的董事会成员。他还曾于2020年11月至2024年4月担任上市临床阶段生物技术公司Antibe Therapeutics Inc.（“Antibe”）的董事会成员、审计委员会成员、人力资源和薪酬委员会成员，并于2022年5月至2024年4月担任Antibe董事会主席。Hoffman先生于2017年4月至2020年10月期间担任上市制药公司Heron Therapeutics, Inc.的高级副总裁兼首席财务官。2015年7月至2016年9月，Hoffman先生在上市生物技术公司AnaptysBio，Inc.担任首席财务官。2012年6月至2015年7月，Hoffman先生在2022年3月被辉瑞 Inc.收购之前，曾担任生物制药公司Arena Pharmaceuticals, Inc.（“Arena”）的财务高级副总裁兼首席财务官。2011年8月至2012年6月，此前的2005年12月至2011年3月，他担任Arena的财务副总裁兼首席财务官，并于1997年至2005年12月担任多个职责不断增加的职务。Hoffman先生曾于2021年9月至2022年5月担任生物制药公司Saniona AB的董事会成员，并于2015年3月至2021年8月担任癌症研究公司Kura Oncology, Inc.的董事会成员。他此前还曾担任分子诊断公司CombiMatrix Corporation、生物制药公司MabVax Therapeutics Holdings，Inc.和临床阶段生物技术公司Aravive, Inc.的董事会成员。Hoffman先生担任生物科学财务官员协会指导委员会成员。Hoffman先生曾担任Financial Executives International圣地亚哥分会的董事和总裁，并担任财务会计准则委员会（FASB）的顾问长达10年（2010年至2020年），就新出现的问题和新的财务指导向美国会计规则制定组织提供建议。Hoffman先生拥有圣博纳文大学的学士学位。
Robert E. Hoffman,served as a director of Kintara since April 2018, as Chairman of Kintara since June 2018, as Chief Executive Officer and President of Kintara since November 2021, and as interim Chief Financial Officer of Kintara since June 1, 2023. Mr. Hoffman served in each of such positions through the completion of the Kintara Merger, as such time he was appointed as a member of the TuHURA Board of Directors. He has served as a member of board of directors of ASLAN Pharmaceuticals, Inc. (Nasdaq: ASLN), a publicly-held, clinical-stage immunology focused biopharmaceutical company, since October 2018, and as a member of the board of directors of FibroGenesis, a clinical-stage regenerative medicine company, since April 2021. He has also served as a member of board of directors, on the audit committee, and on the Human Resources and compensation committee of Antibe Therapeutics Inc. ("Antibe"), a publicly-held clinical-stage biotechnology company, since November 2020, and as Chairman of Antibe's board of directors from May 2022 to April 2024. Mr. Hoffman served as Senior Vice President and Chief Financial Officer of Heron Therapeutics, Inc., a publicly-held pharmaceutical company, from April 2017 to October 2020. From July 2015 to September 2016, Mr. Hoffman served as Chief Financial Officer of AnaptysBio, Inc., a publicly-held biotechnology company. From June 2012 to July 2015, Mr. Hoffman served as the Senior Vice President, Finance and Chief Financial Officer of Arena Pharmaceuticals, Inc. ("Arena"), a biopharmaceutical company, prior to its acquisition by Pfizer Inc. in March 2022. From August 2011 to June 2012 and previously from December 2005 to March 2011, he served as Arena's Vice President, Finance and Chief Financial Officer and in a number of various roles of increasing responsibility from 1997 to December 2005. Mr. Hoffman formerly served as a member of the board of directors of Saniona AB, a biopharmaceutical company, from September 2021 to May 2022, and as a member of the board of directors of Kura Oncology, Inc., a cancer research company, from March 2015 to August 2021. He also previously served as a member of the board of directors of CombiMatrix Corporation, a molecular diagnostics company, MabVax Therapeutics Holdings, Inc., a biopharmaceutical company, and Aravive, Inc., a clinical stage biotechnology company. Mr. Hoffman serves as a member of the steering committee of the Association of Bioscience Financial Officers. Mr. Hoffman formerly served as a director and President of the San Diego Chapter of Financial Executives International and was an advisor to the Financial Accounting Standard Board (FASB) for 10 years (2010 to 2020) advising the United States accounting rulemaking organization on emerging issues and new financial guidance. Mr. Hoffman holds a B.B.A. from St. Bonaventure University. - Robert E. Hoffman，自2018年4月起担任Kintara Therapeutics，Inc.董事，自2018年6月起担任Kintara Therapeutics, Inc.董事长，自2021年11月起担任Kintara Therapeutics, Inc.首席执行官兼总裁，自2023年6月起担任Kintara Therapeutics，Inc.临时首席财务官。自2018年10月起，他担任亚狮康药业，Inc.的董事会成员，该公司是一家上市的、专注于临床阶段免疫学的生物制药公司，自2021年4月起担任FibroGenesis，一家临床阶段再生医学公司的董事会成员。他还曾于2020年11月至2024年4月担任上市临床阶段生物技术公司Antibe Therapeutics Inc.（“Antibe”）的董事会成员、审计委员会成员、人力资源和薪酬委员会成员，并于2022年5月至2024年4月担任Antibe董事会主席。Hoffman先生于2017年4月至2020年10月期间担任上市制药公司Heron Therapeutics, Inc.的高级副总裁兼首席财务官。2015年7月至2016年9月，Hoffman先生在上市生物技术公司AnaptysBio，Inc.担任首席财务官。2012年6月至2015年7月，Hoffman先生在2022年3月被辉瑞 Inc.收购之前，曾担任生物制药公司Arena Pharmaceuticals, Inc.（“Arena”）的财务高级副总裁兼首席财务官。2011年8月至2012年6月，此前的2005年12月至2011年3月，他担任Arena的财务副总裁兼首席财务官，并于1997年至2005年12月担任多个职责不断增加的职务。Hoffman先生曾于2021年9月至2022年5月担任生物制药公司Saniona AB的董事会成员，并于2015年3月至2021年8月担任癌症研究公司Kura Oncology, Inc.的董事会成员。他此前还曾担任分子诊断公司CombiMatrix Corporation、生物制药公司MabVax Therapeutics Holdings，Inc.和临床阶段生物技术公司Aravive, Inc.的董事会成员。Hoffman先生担任生物科学财务官员协会指导委员会成员。Hoffman先生曾担任Financial Executives International圣地亚哥分会的董事和总裁，并担任财务会计准则委员会（FASB）的顾问长达10年（2010年至2020年），就新出现的问题和新的财务指导向美国会计规则制定组织提供建议。Hoffman先生拥有圣博纳文大学的学士学位。
- Robert E. Hoffman,served as a director of Kintara since April 2018, as Chairman of Kintara since June 2018, as Chief Executive Officer and President of Kintara since November 2021, and as interim Chief Financial Officer of Kintara since June 1, 2023. Mr. Hoffman served in each of such positions through the completion of the Kintara Merger, as such time he was appointed as a member of the TuHURA Board of Directors. He has served as a member of board of directors of ASLAN Pharmaceuticals, Inc. (Nasdaq: ASLN), a publicly-held, clinical-stage immunology focused biopharmaceutical company, since October 2018, and as a member of the board of directors of FibroGenesis, a clinical-stage regenerative medicine company, since April 2021. He has also served as a member of board of directors, on the audit committee, and on the Human Resources and compensation committee of Antibe Therapeutics Inc. ("Antibe"), a publicly-held clinical-stage biotechnology company, since November 2020, and as Chairman of Antibe's board of directors from May 2022 to April 2024. Mr. Hoffman served as Senior Vice President and Chief Financial Officer of Heron Therapeutics, Inc., a publicly-held pharmaceutical company, from April 2017 to October 2020. From July 2015 to September 2016, Mr. Hoffman served as Chief Financial Officer of AnaptysBio, Inc., a publicly-held biotechnology company. From June 2012 to July 2015, Mr. Hoffman served as the Senior Vice President, Finance and Chief Financial Officer of Arena Pharmaceuticals, Inc. ("Arena"), a biopharmaceutical company, prior to its acquisition by Pfizer Inc. in March 2022. From August 2011 to June 2012 and previously from December 2005 to March 2011, he served as Arena's Vice President, Finance and Chief Financial Officer and in a number of various roles of increasing responsibility from 1997 to December 2005. Mr. Hoffman formerly served as a member of the board of directors of Saniona AB, a biopharmaceutical company, from September 2021 to May 2022, and as a member of the board of directors of Kura Oncology, Inc., a cancer research company, from March 2015 to August 2021. He also previously served as a member of the board of directors of CombiMatrix Corporation, a molecular diagnostics company, MabVax Therapeutics Holdings, Inc., a biopharmaceutical company, and Aravive, Inc., a clinical stage biotechnology company. Mr. Hoffman serves as a member of the steering committee of the Association of Bioscience Financial Officers. Mr. Hoffman formerly served as a director and President of the San Diego Chapter of Financial Executives International and was an advisor to the Financial Accounting Standard Board (FASB) for 10 years (2010 to 2020) advising the United States accounting rulemaking organization on emerging issues and new financial guidance. Mr. Hoffman holds a B.B.A. from St. Bonaventure University.
- Faheem Hasnain
-
Faheem Hasnain，2010年11月起，他担任我公司总裁、首席执行官和董事。加入我公司前2008年12月至2010年4月被Abbott Laboratories收购，他担任Facet Biotech Corporation的总裁、首席执行官和董事， 该公司是生物推动的抗体公司，主要关注多发性硬化和肿瘤。2008年10月至12月Facet Biotech离开PDL BioPharma，他担任PDL BioPharma, Inc.总裁、首席执行官和董事 ；2004年10月至2008年9月，就职于专注于神经障碍、自体免疫疾病和癌症的生物技术公司Biogen Idec Inc.， 最近担任执行副总裁，负责肿瘤/风湿病战略商业单元。加入Biogen Idec之前，他曾就职于Bristol Myers Squibb担任肿瘤治疗网络总裁， 并在GlaxoSmithKline及其前身工作了14年。2010年11月，他被任命为Ambit Biosciences Corporation的董事会主席，目前是Seragow Pharmaceuticals的董事会成员。2008年起，他担任Sente, Inc.的董事会主席，以及Tercica, Inc., Aragon Pharmaceuticals和Somaxon Pharmaceuticals, Inc.的董事会成员。他在加拿大University of Windsor Ontario获得人体动力学学位和教育学士学位。
Faheem Hasnain has served on our board of directors since August 2016. Mr. Hasnain is currently Executive Chairman since August 2018 and served as Chairman and Chief Executive Officer from October 2015 through July 2018 at Gossamer Bio, Inc. Gossamer Bio is a publicly-traded company focused on the discovery and development of novel and differentiated therapeutic products to address unmet need amongst various targeted patient populations. Previously, Mr. Hasnain served as the Chief Executive Officer, President, and a director at Receptos, Inc. from November 2010 to August 2015. Prior to joining Receptos, Inc., Mr. Hasnain was the President and Chief Executive Officer and a director of Facet Biotech Corporation, a biology-driven antibody company with a focus in multiple sclerosis and oncology. He held that position from December 2008 until the company’s acquisition by Abbott Laboratories in April 2010. Previously, Mr. Hasnain was President, Chief Executive Officer and a director of PDL BioPharma, Inc. from October 2008 until Facet Biotech was spun off from PDL BioPharma in December 2008. From October 2004 to September 2008 Mr. Hasnain was at Biogen Inc., most recently as Executive Vice President in charge of the oncology/rheumatology strategic business unit. Prior to Biogen, Mr. Hasnain held roles with Bristol Myers Squibb, where he was President of the Oncology Therapeutics Network, and for 14 years at GlaxoSmithKline and its predecessor organizations. He serves as Chairman of the board of directors of Sente, Inc. and Tocagen Inc., and has served as a member of the board of directors of Kura Oncology, Inc. He previously served as a member of the board of directors of Ambit Biosciences Corporation, Aragon Pharmaceuticals, Pernix Sleep, Inc., Seragon Pharmaceuticals, Somaxon Pharmaceuticals, Inc. and Tercica, Inc. Mr. Hasnain received a B.H.K. and B.Ed. from the University of Windsor Ontario in Canada. - Faheem Hasnain，2010年11月起，他担任我公司总裁、首席执行官和董事。加入我公司前2008年12月至2010年4月被Abbott Laboratories收购，他担任Facet Biotech Corporation的总裁、首席执行官和董事， 该公司是生物推动的抗体公司，主要关注多发性硬化和肿瘤。2008年10月至12月Facet Biotech离开PDL BioPharma，他担任PDL BioPharma, Inc.总裁、首席执行官和董事 ；2004年10月至2008年9月，就职于专注于神经障碍、自体免疫疾病和癌症的生物技术公司Biogen Idec Inc.， 最近担任执行副总裁，负责肿瘤/风湿病战略商业单元。加入Biogen Idec之前，他曾就职于Bristol Myers Squibb担任肿瘤治疗网络总裁， 并在GlaxoSmithKline及其前身工作了14年。2010年11月，他被任命为Ambit Biosciences Corporation的董事会主席，目前是Seragow Pharmaceuticals的董事会成员。2008年起，他担任Sente, Inc.的董事会主席，以及Tercica, Inc., Aragon Pharmaceuticals和Somaxon Pharmaceuticals, Inc.的董事会成员。他在加拿大University of Windsor Ontario获得人体动力学学位和教育学士学位。
- Faheem Hasnain has served on our board of directors since August 2016. Mr. Hasnain is currently Executive Chairman since August 2018 and served as Chairman and Chief Executive Officer from October 2015 through July 2018 at Gossamer Bio, Inc. Gossamer Bio is a publicly-traded company focused on the discovery and development of novel and differentiated therapeutic products to address unmet need amongst various targeted patient populations. Previously, Mr. Hasnain served as the Chief Executive Officer, President, and a director at Receptos, Inc. from November 2010 to August 2015. Prior to joining Receptos, Inc., Mr. Hasnain was the President and Chief Executive Officer and a director of Facet Biotech Corporation, a biology-driven antibody company with a focus in multiple sclerosis and oncology. He held that position from December 2008 until the company’s acquisition by Abbott Laboratories in April 2010. Previously, Mr. Hasnain was President, Chief Executive Officer and a director of PDL BioPharma, Inc. from October 2008 until Facet Biotech was spun off from PDL BioPharma in December 2008. From October 2004 to September 2008 Mr. Hasnain was at Biogen Inc., most recently as Executive Vice President in charge of the oncology/rheumatology strategic business unit. Prior to Biogen, Mr. Hasnain held roles with Bristol Myers Squibb, where he was President of the Oncology Therapeutics Network, and for 14 years at GlaxoSmithKline and its predecessor organizations. He serves as Chairman of the board of directors of Sente, Inc. and Tocagen Inc., and has served as a member of the board of directors of Kura Oncology, Inc. He previously served as a member of the board of directors of Ambit Biosciences Corporation, Aragon Pharmaceuticals, Pernix Sleep, Inc., Seragon Pharmaceuticals, Somaxon Pharmaceuticals, Inc. and Tercica, Inc. Mr. Hasnain received a B.H.K. and B.Ed. from the University of Windsor Ontario in Canada.
- Thomas Malley
-
Thomas Malley先生，男，美国国籍，学士学位，自2016年起担任百济神州有限公司董事。Malley先生于1991年获得斯坦福大学的生物学学士学位。1991年至2007年期间，Malley先生在Janus MutualFunds工作，担任多项职务。其中，1991年至1998年，Malley先生担任Janus的股票分析师，研究范围包括医疗保健和生物技术股票；1999年至2007年，Malley先生担任JanusGlobal Life SciencesFund的投资组合经理，并领导保健行业分析员团队。自2007年起，Malley先生一直担任MossrockCapital,LLC总裁。此外，Malley先生曾在以下公司担任董事：于2012年至2017年担任OvaScienceInc.董事；2006年至2015年担任Synageva BioPharmaCorp.董事；2011年至2015年担任PumaBiotechnology,Inc.董事；及2007年至2009年担任CougarBiotechnology,Inc.董事。自2015年至今，Malley先生担任KuraOncology,Inc.董事；自2016年至今，其担任KiniksaPharmaceuticals董事。
Thomas Malley,2007-Present:Mossrock Capital, LLC (President);Janus Mutual Funds;Janus Global Life Sciences Fund (Portfolio Manager, Equity Analyst);Other Public Company Directorships:2015-Present: Kura Oncology, Inc.;2016-Present: Kiniksa Pharmaceuticals, Ltd.;Former Public Company Directorships:OvaScience, Inc.;Synageva BioPharma Corp.;Puma Biotechnology, Inc.;Cougar Biotechnology, Inc.;Mr. Malley received a B.S. in Biology from Stanford University in June 1991. - Thomas Malley先生，男，美国国籍，学士学位，自2016年起担任百济神州有限公司董事。Malley先生于1991年获得斯坦福大学的生物学学士学位。1991年至2007年期间，Malley先生在Janus MutualFunds工作，担任多项职务。其中，1991年至1998年，Malley先生担任Janus的股票分析师，研究范围包括医疗保健和生物技术股票；1999年至2007年，Malley先生担任JanusGlobal Life SciencesFund的投资组合经理，并领导保健行业分析员团队。自2007年起，Malley先生一直担任MossrockCapital,LLC总裁。此外，Malley先生曾在以下公司担任董事：于2012年至2017年担任OvaScienceInc.董事；2006年至2015年担任Synageva BioPharmaCorp.董事；2011年至2015年担任PumaBiotechnology,Inc.董事；及2007年至2009年担任CougarBiotechnology,Inc.董事。自2015年至今，Malley先生担任KuraOncology,Inc.董事；自2016年至今，其担任KiniksaPharmaceuticals董事。
- Thomas Malley,2007-Present:Mossrock Capital, LLC (President);Janus Mutual Funds;Janus Global Life Sciences Fund (Portfolio Manager, Equity Analyst);Other Public Company Directorships:2015-Present: Kura Oncology, Inc.;2016-Present: Kiniksa Pharmaceuticals, Ltd.;Former Public Company Directorships:OvaScience, Inc.;Synageva BioPharma Corp.;Puma Biotechnology, Inc.;Cougar Biotechnology, Inc.;Mr. Malley received a B.S. in Biology from Stanford University in June 1991.
- Troy Wilson
-
Troy Wilson是我们的联合创始人，自2012年11月起担任董事会成员，自2019年2月起担任执行主席。Wilson博士于2012年11月至2019年2月担任我们的总裁兼首席执行官。他自2014年8月起担任KuraOncology，Inc.总裁兼首席执行官和董事会成员，自2013年10月起担任PumaBiotechnology，Inc.董事会成员。他也曾一直担任Wellspring Biosciences公司（私人生物制药公司）的董事会执行主席（2012年7月以来），也曾担任Wellspring Biosciences公司（母公司Araxes Pharma公司）的唯一管理成员（2012年5月以来）。此前，威尔逊博士曾于2014年6月至2019年10月担任Zosano Pharma Corporation董事。他还于2012年7月至2019年3月担任Wellspring Biosciences和Araxes Pharma的总裁兼首席执行官，并担任Intellikine，Inc.的总裁兼首席执行官兼董事会成员。Wilson博士拥有纽约大学（New York University）的法学博士学位和加州大学伯克利分校（University of California，Berkeley）的生物有机化学博士学位和生物物理学学士学位。
Troy Wilson is our co-founder and has served as a member of our board of directors since November 2012 and as Executive Chairman since February 2019. Dr. Wilson served as our President and Chief Executive Officer from November 2012 to February 2019. He has been President and Chief Executive Officer and a member of the board of directors of Kura Oncology, Inc. since August 2014 and has served as a member of the board of directors of Puma Biotechnology, Inc. since October 2013. He has also served as Executive Chairman of the board of directors of Wellspring Biosciences, Inc., a privately-held biopharmaceutical company, since July 2012 and has served as the sole managing member of Wellspring Biosciences’ parent company, Araxes Pharma LLC, since May 2012. Previously, Dr. Wilson served as a director of Zosano Pharma Corporation from June 2014 to October 2019. He also served as President and Chief Executive Officer of Wellspring Biosciences and Araxes Pharma from July 2012 to March 2019 and as President and Chief Executive Officer and a member of the board of directors of Intellikine, Inc. Dr. Wilson holds a J.D. from New York University and a Ph.D. in Bioorganic Chemistry and a B.A. in Biophysics from the University of California, Berkeley. - Troy Wilson是我们的联合创始人，自2012年11月起担任董事会成员，自2019年2月起担任执行主席。Wilson博士于2012年11月至2019年2月担任我们的总裁兼首席执行官。他自2014年8月起担任KuraOncology，Inc.总裁兼首席执行官和董事会成员，自2013年10月起担任PumaBiotechnology，Inc.董事会成员。他也曾一直担任Wellspring Biosciences公司（私人生物制药公司）的董事会执行主席（2012年7月以来），也曾担任Wellspring Biosciences公司（母公司Araxes Pharma公司）的唯一管理成员（2012年5月以来）。此前，威尔逊博士曾于2014年6月至2019年10月担任Zosano Pharma Corporation董事。他还于2012年7月至2019年3月担任Wellspring Biosciences和Araxes Pharma的总裁兼首席执行官，并担任Intellikine，Inc.的总裁兼首席执行官兼董事会成员。Wilson博士拥有纽约大学（New York University）的法学博士学位和加州大学伯克利分校（University of California，Berkeley）的生物有机化学博士学位和生物物理学学士学位。
- Troy Wilson is our co-founder and has served as a member of our board of directors since November 2012 and as Executive Chairman since February 2019. Dr. Wilson served as our President and Chief Executive Officer from November 2012 to February 2019. He has been President and Chief Executive Officer and a member of the board of directors of Kura Oncology, Inc. since August 2014 and has served as a member of the board of directors of Puma Biotechnology, Inc. since October 2013. He has also served as Executive Chairman of the board of directors of Wellspring Biosciences, Inc., a privately-held biopharmaceutical company, since July 2012 and has served as the sole managing member of Wellspring Biosciences’ parent company, Araxes Pharma LLC, since May 2012. Previously, Dr. Wilson served as a director of Zosano Pharma Corporation from June 2014 to October 2019. He also served as President and Chief Executive Officer of Wellspring Biosciences and Araxes Pharma from July 2012 to March 2019 and as President and Chief Executive Officer and a member of the board of directors of Intellikine, Inc. Dr. Wilson holds a J.D. from New York University and a Ph.D. in Bioorganic Chemistry and a B.A. in Biophysics from the University of California, Berkeley.
高管简历
中英对照 | 中文 | 英文- Yi Liu
Yi Liu， 是哲学博士。2015年3月公司合并以来，他一直担任我们的首席科学官。他于2014年8月共同创立Prior Kura公司，也曾担任Prior Kura的首席科学官（始于2014年10月），直到2015年3月上游合并。此前，他曾共同创立并担任Wellspring Biosciences LLC（一个私人生物制药公司）的首席科学官（2012年7月至2014年9月）。他也曾共同创立Intellikine, Inc.（一个私人生物制药公司），在那里他曾担任药物发现副总裁（2007年至2012年5月），直到公司被Takeda Pharmaceutical Company Limited收购。任职Intellikine公司之前，他曾担任the Genomics Institute of the Novartis Research Foundation的药物设计集团主管。职业生涯早期，他也曾担任高级科学职务，任职于SGX Pharmaceuticals, Inc（一个公共生物制药公司，于2008年被Eli Lilly and Company收购）、Curagen Corporation（一个公共生物制药发展公司）。他持有Princeton University的生物化学博士学位、Beijing University的计算化学硕士学位，以及Tsinghua University的化学工程学士学位。
Yi Liu, Ph.D. has served as our Chief Scientific Officer since the Merger in March 2015. Dr. Liu co-founded Prior Kura in August 2014 and served as the Chief Scientific Officer of Prior Kura from October 2014 until the Upstream Merger in March 2015. Prior to that, Dr. Liu co-founded and served as Chief Scientific Officer of Wellspring Biosciences LLC, a private biopharmaceutical company, from July 2012 to September 2014. Dr. Liu also co-founded Intellikine, Inc., a private biopharmaceutical company, where he served as Vice President of Drug Discovery from 2007 to May 2012, until its acquisition by Takeda Pharmaceutical Company Limited. Prior to Intellikine, Dr. Liu was the head of the drug design group at the Genomics Institute of the Novartis Research Foundation. Earlier in his career, he held senior scientist positions at both SGX Pharmaceuticals, Inc., a public biopharmaceutical company which was acquired by Eli Lilly and Company in 2008, and Curagen Corporation, a public biopharmaceutical development company. Dr. Liu received his Ph.D. in Biochemistry from Princeton University, his MSc in computational chemistry from Beijing University and his BE in Chemical Engineering from Tsinghua University.- Yi Liu， 是哲学博士。2015年3月公司合并以来，他一直担任我们的首席科学官。他于2014年8月共同创立Prior Kura公司，也曾担任Prior Kura的首席科学官（始于2014年10月），直到2015年3月上游合并。此前，他曾共同创立并担任Wellspring Biosciences LLC（一个私人生物制药公司）的首席科学官（2012年7月至2014年9月）。他也曾共同创立Intellikine, Inc.（一个私人生物制药公司），在那里他曾担任药物发现副总裁（2007年至2012年5月），直到公司被Takeda Pharmaceutical Company Limited收购。任职Intellikine公司之前，他曾担任the Genomics Institute of the Novartis Research Foundation的药物设计集团主管。职业生涯早期，他也曾担任高级科学职务，任职于SGX Pharmaceuticals, Inc（一个公共生物制药公司，于2008年被Eli Lilly and Company收购）、Curagen Corporation（一个公共生物制药发展公司）。他持有Princeton University的生物化学博士学位、Beijing University的计算化学硕士学位，以及Tsinghua University的化学工程学士学位。
- Yi Liu, Ph.D. has served as our Chief Scientific Officer since the Merger in March 2015. Dr. Liu co-founded Prior Kura in August 2014 and served as the Chief Scientific Officer of Prior Kura from October 2014 until the Upstream Merger in March 2015. Prior to that, Dr. Liu co-founded and served as Chief Scientific Officer of Wellspring Biosciences LLC, a private biopharmaceutical company, from July 2012 to September 2014. Dr. Liu also co-founded Intellikine, Inc., a private biopharmaceutical company, where he served as Vice President of Drug Discovery from 2007 to May 2012, until its acquisition by Takeda Pharmaceutical Company Limited. Prior to Intellikine, Dr. Liu was the head of the drug design group at the Genomics Institute of the Novartis Research Foundation. Earlier in his career, he held senior scientist positions at both SGX Pharmaceuticals, Inc., a public biopharmaceutical company which was acquired by Eli Lilly and Company in 2008, and Curagen Corporation, a public biopharmaceutical development company. Dr. Liu received his Ph.D. in Biochemistry from Princeton University, his MSc in computational chemistry from Beijing University and his BE in Chemical Engineering from Tsinghua University.
- Heidi Henson
Heidi Henson，自2015年3月合并起担任首席财务官兼秘书；2014年8月至2015年3月上游兼并期间担任 Prior Kura的首席财务官兼秘书；自2012年7月起担任Wellspring Biosciences LLC（私营生物制药公司，母公司是Araxes Pharma LLC）的首席财务官兼秘书；2007年至2012年3月间担任Intellikine, Inc.（私营生物制药公司）的财务副总裁，直至其被Takeda Pharmaceutical Company Limited收购。数年来，她是一名独立金融顾问，协助多家早期公司的启动活动、美国证券交易委员会报告、《萨班斯-奥克斯利法案（Sarbanes-Oxley）》的实施和遵守。她此前是Anadys Pharmaceuticals, Inc.（上市的生物制药公司）的财务主管，在Fair Isaac & Co., Inc.（前称HNC Software, Inc.， 上市软件公司）担任多项管理职位。她事业起步于在PricewaterhouseCoopers LLP（上市会计公司）的审计师经历，负责各类企业。她获得了San Diego大学的会计学学士学位，是一名注册会计师。
Heidi Henson,has been a director of the Company since June 1, 2023. Ms. Henson served as the Chief Financial Officer of Pardes Biosciences, Inc., a publicly listed biopharmaceutical company, from January 2021 until September 2023. Prior to that, she was a financial consultant for the same company from 2020 until her appointment as Chief Financial Officer. From 2019 through July 2020, she was the Chief Financial Officer of Imbria Pharmaceuticals, Inc., a private biopharmaceutical company. From 2018 through 2019, she was the Chief Financial Officer of Respivant Sciences, Inc., a private biopharmaceutical company. From 2014 through 2018, she was the Chief Financial Officer of Kura Oncology, Inc., a publicly listed biopharmaceuticals company. From 2012 through 2018, Ms. Henson was the Chief Financial Officer for Wellspring Biosciences LLC and Araxes Pharma LLC (its parent company), a private biopharmaceutical company. Ms. Henson currently serves on the board of directors of PepGen, Inc. (NASDAQ: PEPG) and Lisata Therapeutics, Inc. (NASDAQ: LSTA), both publicly traded, clinical-stage biotechnology companies, and she serves as the chair of both of their audit committees. Ms. Henson holds a Bachelor of Accountancy from the University of San Diego and is a Certified Public Accountant (inactive).- Heidi Henson，自2015年3月合并起担任首席财务官兼秘书；2014年8月至2015年3月上游兼并期间担任 Prior Kura的首席财务官兼秘书；自2012年7月起担任Wellspring Biosciences LLC（私营生物制药公司，母公司是Araxes Pharma LLC）的首席财务官兼秘书；2007年至2012年3月间担任Intellikine, Inc.（私营生物制药公司）的财务副总裁，直至其被Takeda Pharmaceutical Company Limited收购。数年来，她是一名独立金融顾问，协助多家早期公司的启动活动、美国证券交易委员会报告、《萨班斯-奥克斯利法案（Sarbanes-Oxley）》的实施和遵守。她此前是Anadys Pharmaceuticals, Inc.（上市的生物制药公司）的财务主管，在Fair Isaac & Co., Inc.（前称HNC Software, Inc.， 上市软件公司）担任多项管理职位。她事业起步于在PricewaterhouseCoopers LLP（上市会计公司）的审计师经历，负责各类企业。她获得了San Diego大学的会计学学士学位，是一名注册会计师。
- Heidi Henson,has been a director of the Company since June 1, 2023. Ms. Henson served as the Chief Financial Officer of Pardes Biosciences, Inc., a publicly listed biopharmaceutical company, from January 2021 until September 2023. Prior to that, she was a financial consultant for the same company from 2020 until her appointment as Chief Financial Officer. From 2019 through July 2020, she was the Chief Financial Officer of Imbria Pharmaceuticals, Inc., a private biopharmaceutical company. From 2018 through 2019, she was the Chief Financial Officer of Respivant Sciences, Inc., a private biopharmaceutical company. From 2014 through 2018, she was the Chief Financial Officer of Kura Oncology, Inc., a publicly listed biopharmaceuticals company. From 2012 through 2018, Ms. Henson was the Chief Financial Officer for Wellspring Biosciences LLC and Araxes Pharma LLC (its parent company), a private biopharmaceutical company. Ms. Henson currently serves on the board of directors of PepGen, Inc. (NASDAQ: PEPG) and Lisata Therapeutics, Inc. (NASDAQ: LSTA), both publicly traded, clinical-stage biotechnology companies, and she serves as the chair of both of their audit committees. Ms. Henson holds a Bachelor of Accountancy from the University of San Diego and is a Certified Public Accountant (inactive).
- Antonio Gualberto
Antonio Gualberto，自2015年3月合并起担任我公司首席医疗官。他于2014年8月联合成立Prior Kura，2014年10月至2015年3月上游兼并期间担任其首席医疗官。2012年6月至2014年9月，他是EMD Serono, Inc.（位于德国达姆施塔特Merck KGaA（全球制药和化学药品集团）在美国的生物制药子公司）的肿瘤全球临床开发中心主任；2010年9月至2012年4月间担任the Takeda Oncology Company（私营生物制药公司）的临床研究主管；1999年10月至2010年8月，他在Pfizer, Inc.（上市生物制药公司）担任多个职位，包括临床开发与医学业务高级主管、全球临床主管等。他也担任了多个学术职位，包括The Warren Alpert Medical School of Brown University的病理学和实验医学临时副教授。他获得了Trinidad College的学士学位，西班牙the University of Seville的医学和哲学博士学位，在Case Western Reserve University和the University of North Carolina的Chapel Hill Lineberger Comprehensive Cancer Center得到博士后研究训练。
Antonio Gualberto has served as our Chief Medical Officer since the Merger in March 2015. Dr. Gualberto co-founded Prior Kura in August 2014 and served as the Chief Medical Officer of Prior Kura from October 2014 until the Upstream Merger in March 2015. From June 2012 to September 2014 Dr. Gualberto served as the head of the global clinical development center for oncology at EMD Serono, Inc., the biopharmaceutical subsidiary in the United States of Merck KGaA, Darmstadt, Germany, a global pharmaceutical and chemical group. Prior to this, from September 2010 to April 2012 Dr. Gualberto served as a group head of clinical research for the Takeda Oncology Company, a privately-held biopharmaceutical company. From October 1999 to August 2010 Dr. Gualberto served in varying roles at Pfizer, Inc., a publicly-held pharmaceutical company, including Senior Director, Clinical Development and Medical Affairs, and Global Clinical Leader. He has also held several academic positions including, from October 2008 to June 2012 an adjunct appointment of associate professor of pathology and laboratory medicine at The Warren Alpert Medical School of Brown University. Dr. Gualberto received his B.S. from Trinidad College and M.D. and Ph.D. degrees from the University of Seville in Spain. He received postgraduate fellowship training at Case Western Reserve University and the University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center.- Antonio Gualberto，自2015年3月合并起担任我公司首席医疗官。他于2014年8月联合成立Prior Kura，2014年10月至2015年3月上游兼并期间担任其首席医疗官。2012年6月至2014年9月，他是EMD Serono, Inc.（位于德国达姆施塔特Merck KGaA（全球制药和化学药品集团）在美国的生物制药子公司）的肿瘤全球临床开发中心主任；2010年9月至2012年4月间担任the Takeda Oncology Company（私营生物制药公司）的临床研究主管；1999年10月至2010年8月，他在Pfizer, Inc.（上市生物制药公司）担任多个职位，包括临床开发与医学业务高级主管、全球临床主管等。他也担任了多个学术职位，包括The Warren Alpert Medical School of Brown University的病理学和实验医学临时副教授。他获得了Trinidad College的学士学位，西班牙the University of Seville的医学和哲学博士学位，在Case Western Reserve University和the University of North Carolina的Chapel Hill Lineberger Comprehensive Cancer Center得到博士后研究训练。
- Antonio Gualberto has served as our Chief Medical Officer since the Merger in March 2015. Dr. Gualberto co-founded Prior Kura in August 2014 and served as the Chief Medical Officer of Prior Kura from October 2014 until the Upstream Merger in March 2015. From June 2012 to September 2014 Dr. Gualberto served as the head of the global clinical development center for oncology at EMD Serono, Inc., the biopharmaceutical subsidiary in the United States of Merck KGaA, Darmstadt, Germany, a global pharmaceutical and chemical group. Prior to this, from September 2010 to April 2012 Dr. Gualberto served as a group head of clinical research for the Takeda Oncology Company, a privately-held biopharmaceutical company. From October 1999 to August 2010 Dr. Gualberto served in varying roles at Pfizer, Inc., a publicly-held pharmaceutical company, including Senior Director, Clinical Development and Medical Affairs, and Global Clinical Leader. He has also held several academic positions including, from October 2008 to June 2012 an adjunct appointment of associate professor of pathology and laboratory medicine at The Warren Alpert Medical School of Brown University. Dr. Gualberto received his B.S. from Trinidad College and M.D. and Ph.D. degrees from the University of Seville in Spain. He received postgraduate fellowship training at Case Western Reserve University and the University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center.
- Annette North
Annette North，自2015年3月合并起担任高级副总裁兼总顾问；2015年1月至2015年3月上游兼并期间担任Prior Kura的高级副总裁兼总顾问。她也是Wellspring Biosciences LLC及其母公司Araxes Pharma LLC的总顾问兼秘书。在加入我公司之前，2013年6月至2015年1月间，她是Ambit Biosciences Corporation（上市生物制药公司）的高级副总裁兼总顾问，在此期间Ambit完成了其首次公开发售，被Daiichi Sankyo Company Limited收购；2009年1月至2014年12月间担任多家生命科学公司的独立法律顾问；2000年至2008年，她是SGX Pharmaceuticals, Inc.（上市生物制药公司，2008年被Eli Lilly and Company收购）的总顾问，并担任多项其他职位。她早期曾担任Axys Pharmaceuticals, Inc.（生物制药公司）的运营及法律高级主管、Sequana Therapeutics, Inc.（生物制药公司）的法律事务主管。她获得了澳大利亚the University of Melbourne商学和法学双学士学位。
Annette North has been appointed to serve as our Executive Vice President, General Counsel and Secretary effective April 15 2019. Previously, Ms. North served as Senior Vice President, General Counsel of Kura Oncology, Inc., a publicly held clinical-stage biopharmaceutical company, from January 2015 to April 2019 and as General Counsel and Secretary of Wellspring Biosciences, Inc. and its parent company, Araxes Pharma LLC. Ms. North served as Senior Vice President and General Counsel of Ambit Biosciences Corporation, a publicly held biopharmaceutical company, from June 2013 to January 2015 during which time Ambit completed its initial public offering and was acquired by Daiichi Sankyo Company Limited. From January 2009 to December 2014 Ms. North was an independent legal consultant to a number of life sciences companies. From 2000 to 2008 Ms. North served as General Counsel and held a number of other positions at SGX Pharmaceuticals, Inc., a publicly held biopharmaceutical company which was acquired by Eli Lilly and Company in 2008. Earlier in her career, Ms. North served as Senior Director of Operations and Legal at Axys Pharmaceuticals, Inc., a biopharmaceutical company, and Director of Legal Affairs at Sequana Therapeutics, Inc., a biopharmaceutical company. Ms. North received both her Bachelor of Commerce and her Bachelor of Laws from the University of Melbourne, Australia.- Annette North，自2015年3月合并起担任高级副总裁兼总顾问；2015年1月至2015年3月上游兼并期间担任Prior Kura的高级副总裁兼总顾问。她也是Wellspring Biosciences LLC及其母公司Araxes Pharma LLC的总顾问兼秘书。在加入我公司之前，2013年6月至2015年1月间，她是Ambit Biosciences Corporation（上市生物制药公司）的高级副总裁兼总顾问，在此期间Ambit完成了其首次公开发售，被Daiichi Sankyo Company Limited收购；2009年1月至2014年12月间担任多家生命科学公司的独立法律顾问；2000年至2008年，她是SGX Pharmaceuticals, Inc.（上市生物制药公司，2008年被Eli Lilly and Company收购）的总顾问，并担任多项其他职位。她早期曾担任Axys Pharmaceuticals, Inc.（生物制药公司）的运营及法律高级主管、Sequana Therapeutics, Inc.（生物制药公司）的法律事务主管。她获得了澳大利亚the University of Melbourne商学和法学双学士学位。
- Annette North has been appointed to serve as our Executive Vice President, General Counsel and Secretary effective April 15 2019. Previously, Ms. North served as Senior Vice President, General Counsel of Kura Oncology, Inc., a publicly held clinical-stage biopharmaceutical company, from January 2015 to April 2019 and as General Counsel and Secretary of Wellspring Biosciences, Inc. and its parent company, Araxes Pharma LLC. Ms. North served as Senior Vice President and General Counsel of Ambit Biosciences Corporation, a publicly held biopharmaceutical company, from June 2013 to January 2015 during which time Ambit completed its initial public offering and was acquired by Daiichi Sankyo Company Limited. From January 2009 to December 2014 Ms. North was an independent legal consultant to a number of life sciences companies. From 2000 to 2008 Ms. North served as General Counsel and held a number of other positions at SGX Pharmaceuticals, Inc., a publicly held biopharmaceutical company which was acquired by Eli Lilly and Company in 2008. Earlier in her career, Ms. North served as Senior Director of Operations and Legal at Axys Pharmaceuticals, Inc., a biopharmaceutical company, and Director of Legal Affairs at Sequana Therapeutics, Inc., a biopharmaceutical company. Ms. North received both her Bachelor of Commerce and her Bachelor of Laws from the University of Melbourne, Australia.
- Pingda Ren
Pingda Ren，自2015年3月合并起担任我公司化学和制药科学高级副总裁。他于2014年8月联合成立Prior Kura，并于2014年10月至2015年3月上游兼并期间担任其化学和制药科学高级副总裁。此前，他联合成立了Wellspring Biosciences LLC（私营生物制药公司），并于2012年7月至2014年9月间担任其化学高级副总裁。他也联合成立了Intellikine, Inc.（私营生物制药公司），2007年至2012年5月公司被Takeda Pharmaceutical Company Limited收购期间担任化学副总裁。此前，他是Genomics Institute of the Novartis Research Foundation的高级研究员。他早期是Albany Molecular Research Inc.（上市的全球契约研究与制造组织）的高级研究化学家。他获得了Fudan University in China的化学学士和博士学位，在Huw M. L. Davies教授的带领下，于布法罗State University of New York完成了他的博士后研究。
Pingda Ren has served as our Senior Vice President of Chemistry and Pharmaceutical Sciences since the Merger in March 2015. Dr. Ren co-founded Prior Kura in August 2014 and served as the Senior Vice President of Chemistry and Pharmaceutical Sciences of Prior Kura from October 2014 until the Upstream Merger in March 2015. Prior to that, Dr. Ren co-founded and served as Senior Vice President of Chemistry of Wellspring Biosciences, Inc., a privately-held biopharmaceutical company, from July 2012 to September 2014. Dr. Ren also co-founded Intellikine, Inc., a privately-held biopharmaceutical company, where he served as Vice President of Chemistry from 2007 to May 2012 until its acquisition by Takeda Pharmaceutical Company Limited. Prior to Intellikine, Dr. Ren was a Senior Research Investigator in Genomics Institute of the Novartis Research Foundation. Earlier in his career, Dr. Ren was a Senior Research Chemist at Albany Molecular Research Inc., a publicly-held global contract research and manufacturing organization. Dr. Ren earned his B.A and Ph.D. of Chemistry from Fudan University in China. He completed his postdoctoral research with Professor Huw M. L. Davies at State University of New York at Buffalo.- Pingda Ren，自2015年3月合并起担任我公司化学和制药科学高级副总裁。他于2014年8月联合成立Prior Kura，并于2014年10月至2015年3月上游兼并期间担任其化学和制药科学高级副总裁。此前，他联合成立了Wellspring Biosciences LLC（私营生物制药公司），并于2012年7月至2014年9月间担任其化学高级副总裁。他也联合成立了Intellikine, Inc.（私营生物制药公司），2007年至2012年5月公司被Takeda Pharmaceutical Company Limited收购期间担任化学副总裁。此前，他是Genomics Institute of the Novartis Research Foundation的高级研究员。他早期是Albany Molecular Research Inc.（上市的全球契约研究与制造组织）的高级研究化学家。他获得了Fudan University in China的化学学士和博士学位，在Huw M. L. Davies教授的带领下，于布法罗State University of New York完成了他的博士后研究。
- Pingda Ren has served as our Senior Vice President of Chemistry and Pharmaceutical Sciences since the Merger in March 2015. Dr. Ren co-founded Prior Kura in August 2014 and served as the Senior Vice President of Chemistry and Pharmaceutical Sciences of Prior Kura from October 2014 until the Upstream Merger in March 2015. Prior to that, Dr. Ren co-founded and served as Senior Vice President of Chemistry of Wellspring Biosciences, Inc., a privately-held biopharmaceutical company, from July 2012 to September 2014. Dr. Ren also co-founded Intellikine, Inc., a privately-held biopharmaceutical company, where he served as Vice President of Chemistry from 2007 to May 2012 until its acquisition by Takeda Pharmaceutical Company Limited. Prior to Intellikine, Dr. Ren was a Senior Research Investigator in Genomics Institute of the Novartis Research Foundation. Earlier in his career, Dr. Ren was a Senior Research Chemist at Albany Molecular Research Inc., a publicly-held global contract research and manufacturing organization. Dr. Ren earned his B.A and Ph.D. of Chemistry from Fudan University in China. He completed his postdoctoral research with Professor Huw M. L. Davies at State University of New York at Buffalo.
- Troy Wilson
Troy Wilson是我们的联合创始人，自2012年11月起担任董事会成员，自2019年2月起担任执行主席。Wilson博士于2012年11月至2019年2月担任我们的总裁兼首席执行官。他自2014年8月起担任KuraOncology，Inc.总裁兼首席执行官和董事会成员，自2013年10月起担任PumaBiotechnology，Inc.董事会成员。他也曾一直担任Wellspring Biosciences公司（私人生物制药公司）的董事会执行主席（2012年7月以来），也曾担任Wellspring Biosciences公司（母公司Araxes Pharma公司）的唯一管理成员（2012年5月以来）。此前，威尔逊博士曾于2014年6月至2019年10月担任Zosano Pharma Corporation董事。他还于2012年7月至2019年3月担任Wellspring Biosciences和Araxes Pharma的总裁兼首席执行官，并担任Intellikine，Inc.的总裁兼首席执行官兼董事会成员。Wilson博士拥有纽约大学（New York University）的法学博士学位和加州大学伯克利分校（University of California，Berkeley）的生物有机化学博士学位和生物物理学学士学位。
Troy Wilson is our co-founder and has served as a member of our board of directors since November 2012 and as Executive Chairman since February 2019. Dr. Wilson served as our President and Chief Executive Officer from November 2012 to February 2019. He has been President and Chief Executive Officer and a member of the board of directors of Kura Oncology, Inc. since August 2014 and has served as a member of the board of directors of Puma Biotechnology, Inc. since October 2013. He has also served as Executive Chairman of the board of directors of Wellspring Biosciences, Inc., a privately-held biopharmaceutical company, since July 2012 and has served as the sole managing member of Wellspring Biosciences’ parent company, Araxes Pharma LLC, since May 2012. Previously, Dr. Wilson served as a director of Zosano Pharma Corporation from June 2014 to October 2019. He also served as President and Chief Executive Officer of Wellspring Biosciences and Araxes Pharma from July 2012 to March 2019 and as President and Chief Executive Officer and a member of the board of directors of Intellikine, Inc. Dr. Wilson holds a J.D. from New York University and a Ph.D. in Bioorganic Chemistry and a B.A. in Biophysics from the University of California, Berkeley.- Troy Wilson是我们的联合创始人，自2012年11月起担任董事会成员，自2019年2月起担任执行主席。Wilson博士于2012年11月至2019年2月担任我们的总裁兼首席执行官。他自2014年8月起担任KuraOncology，Inc.总裁兼首席执行官和董事会成员，自2013年10月起担任PumaBiotechnology，Inc.董事会成员。他也曾一直担任Wellspring Biosciences公司（私人生物制药公司）的董事会执行主席（2012年7月以来），也曾担任Wellspring Biosciences公司（母公司Araxes Pharma公司）的唯一管理成员（2012年5月以来）。此前，威尔逊博士曾于2014年6月至2019年10月担任Zosano Pharma Corporation董事。他还于2012年7月至2019年3月担任Wellspring Biosciences和Araxes Pharma的总裁兼首席执行官，并担任Intellikine，Inc.的总裁兼首席执行官兼董事会成员。Wilson博士拥有纽约大学（New York University）的法学博士学位和加州大学伯克利分校（University of California，Berkeley）的生物有机化学博士学位和生物物理学学士学位。
- Troy Wilson is our co-founder and has served as a member of our board of directors since November 2012 and as Executive Chairman since February 2019. Dr. Wilson served as our President and Chief Executive Officer from November 2012 to February 2019. He has been President and Chief Executive Officer and a member of the board of directors of Kura Oncology, Inc. since August 2014 and has served as a member of the board of directors of Puma Biotechnology, Inc. since October 2013. He has also served as Executive Chairman of the board of directors of Wellspring Biosciences, Inc., a privately-held biopharmaceutical company, since July 2012 and has served as the sole managing member of Wellspring Biosciences’ parent company, Araxes Pharma LLC, since May 2012. Previously, Dr. Wilson served as a director of Zosano Pharma Corporation from June 2014 to October 2019. He also served as President and Chief Executive Officer of Wellspring Biosciences and Araxes Pharma from July 2012 to March 2019 and as President and Chief Executive Officer and a member of the board of directors of Intellikine, Inc. Dr. Wilson holds a J.D. from New York University and a Ph.D. in Bioorganic Chemistry and a B.A. in Biophysics from the University of California, Berkeley.